Boost For India’s Generic Pharma Majors
Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a growing market.
biocon biologics
October 2024
December 2023
October 2023
July 2023
November 2022
June 2022
February 2022
December 2021
November 2021
Biocon shares rise 2% on deal with Sandoz
Biocon Biologics, a subsidiary of Biocon, has signed a distribution agreement with Sandoz for an immunity-linked injection in Japan.
Biocon shares surge 3% on integration of Viatris’ biosimilar business in 31 European countries
Biocon Biologics acquired the global biosimilar business of Viatris in November last year.
Biocon shares drop 6% after USFDA inspection of Malaysian unit
The OAI status may cause delay or withholding of pending product approvals or supplements from the facility, Biocon says
Healthcare sector M&A deals surge 85% in H1FY23: Grant Thornton
A few high-value transactions played a significant role in driving the total transaction value from $1.2 billion in Q1 2023 to $4.4 billion in H1 2023
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
